Each month the Lupus Forum Steering Committee selects the latest published original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
Literature Highlights - July 2023
Medication Cost Concerns, Voclosporin, RIFLE-LN, Neuropsychiatric Lupus
Literature Highlights - June 2023
Belimumab, Antimalarials, Extra-renal Systemic Lupus Erythematosus, BI 655064, Remission, Infection Risk, Rituximab, Belimumab, Neuropsychiatric Flares
Literature Highlights - May 2023
Litifilimab, Cutaneous Lupus Erythematosus, Longitudinal Autoantibody Profiles, Belimumab, Anifrolumab, Systemic Lupus Erythematosus, RISE
Literature Highlights - March 2023
Baricitinib, EULAR, Interferon Production, Lupus Nephritis, Belimumab
Literature Highlights - February 2023
long term economic burden, neurologic, psychiatric, international, multi-ethnic, SLE, criteria, classification, damage, lupus, prognosis, autoimmune diseases, biological therapy, glucocorticoids, systemic lupus erythematosus, health-related quality of life, interferon signature, SLEDAI, transcriptomic, patient-reported outcome, fatigue, disease activity, mediation analysis
Literature Highlights - January 2023
systematic review, targeted treatments, biologics, clinical trial, belimumab, anifrolumab, Bruton’s Tyrosine Kinase, BTK, inhibitor, evobrutinib, SLE, systemic lupus erythematosus, dose-ranging, pregnancy, obstetric comorbidities, , childhood-onset SLE (cSLE), treatment, safety, CD40 ligand, dapirolizumab pegol, exposure-response, population pharmacokinetics
Literature Highlights - December 2022
biologicals, b-lymphocytes, biomarkers, systemic lupus erythematosus, deucravacitinib, TYK2, Phase II, anifrolumab, Phase III, long-term, safety, IL-2, interleukin-2, Treg, SLE
